Sulfinpyrazone has no effect on the insulin requirements of diabetics, nor does it affect the diabetic control of patients taking glibenclamide (glyburide). Sulfinpyrazone reduces the clearance of tolbutamide, but as yet there appear to be no case reports of this interaction. Sulfinpyrazone modestly increased the AUC of nateglinide, but this is unlikely to be clinically relevant.
No action needed.
© 2006-2022 Last Updated On: 05/17/2022 (0)
Wait 20 seconds...!!!